Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Alpha Tau Medical Ltd. Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme October 21, 2024 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Treats First Patient with Recurrent Lung Cancer October 10, 2024 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC September 20, 2024 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers June 25, 2024 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer May 13, 2024 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 20, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer November 28, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer November 20, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility October 30, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board October 24, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center September 14, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT August 17, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University May 17, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open May 11, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial April 03, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial March 08, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases March 01, 2023 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau to Present at Upcoming November Investor Conferences November 09, 2022 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology October 21, 2022 From Alpha Tau Medical Ltd. Via GlobeNewswire Tickers DRTS DRTSW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
